Bavarian Nordic (OTCMKTS:BVNRY) Stock Crosses Above Fifty Day Moving Average – Should You Sell?

Bavarian Nordic (OTCMKTS:BVNRY)’s share price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $10.08 and traded as high as $10.2650. Bavarian Nordic shares last traded at $10.2650, with a volume of 195 shares trading hands.

Bavarian Nordic Trading Up 0.7%

The company has a market capitalization of $2.44 billion, a PE ratio of 6.62 and a beta of 1.36. The stock’s fifty day moving average is $10.08 and its two-hundred day moving average is $11.10.

Bavarian Nordic (OTCMKTS:BVNRY) last posted its quarterly earnings data on Friday, November 14th. The company reported $0.72 earnings per share (EPS) for the quarter. The business had revenue of $281.11 million during the quarter. Bavarian Nordic had a net margin of 35.96% and a return on equity of 20.47%. As a group, analysts anticipate that Bavarian Nordic will post 0.67 EPS for the current fiscal year.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.